This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Case Report
Amir Abdoli
Jahrom University of Medical Sciences, Jahrom, Iran
Corresponding Author
ORCiD: https://orcid.org/0000-0003-4326-4586
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Declarations:
Declarations
- This study involved human subjects.
- The author confirmed that all appropriate ethical guidelines for the use of human subjects have been followed, any necessary IRB and/or ethics committee review has been obtained, and information about the IRB/ethics committee is included in the manuscript.
- The author has confirmed that all necessary patient/participant consent or assent has been obtained and the appropriate institutional forms have been archived. If the IRB/ethics committee waived the requirement for patient/participant consent or assent, an explanation for the waiver is included in the text.
- This study is a case report.
- The author has confirmed that consent for publication of clinical details and/or clinical images was obtained from the patient/parent/guardian/relative of the patient or waiver of such consent is described in the text.
- The author has confirmed that a statement listing potential conflicts of interest or lack thereof is included in the text.
View the published article here.
Rheumatoid Arthritis (RA) patients usually managed with immunosuppressive agents and they are at a higher risk of infections. There are limited data regarding RA patients with COVID-19. This article reports a RA patient with an acute SARS‐CoV‐2 infection that successfully managed by dose reduction of immunosuppressive medication.
Keywords
SARS-CoV-2, COVID-19, Rheumatoid Arthritis, immunosuppressive therapy
Figure 1
This is a list of supplementary files associated with this preprint. Click to download.
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 2
Posted 18 Nov, 2020
Published
On 18 Sep, 2020
No community comments so far
No comments provided
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Immunology
Learn more about our company.
This is a preprint. It has not completed peer review.
Case Report
Amir Abdoli
Jahrom University of Medical Sciences, Jahrom, Iran
Corresponding Author
ORCiD: https://orcid.org/0000-0003-4326-4586
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 2
Posted 18 Nov, 2020
Published
On 18 Sep, 2020
No community comments so far
No comments provided
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Immunology
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Declarations:
Declarations
- This study involved human subjects.
- The author confirmed that all appropriate ethical guidelines for the use of human subjects have been followed, any necessary IRB and/or ethics committee review has been obtained, and information about the IRB/ethics committee is included in the manuscript.
- The author has confirmed that all necessary patient/participant consent or assent has been obtained and the appropriate institutional forms have been archived. If the IRB/ethics committee waived the requirement for patient/participant consent or assent, an explanation for the waiver is included in the text.
- This study is a case report.
- The author has confirmed that consent for publication of clinical details and/or clinical images was obtained from the patient/parent/guardian/relative of the patient or waiver of such consent is described in the text.
- The author has confirmed that a statement listing potential conflicts of interest or lack thereof is included in the text.
View the published article here.
Rheumatoid Arthritis (RA) patients usually managed with immunosuppressive agents and they are at a higher risk of infections. There are limited data regarding RA patients with COVID-19. This article reports a RA patient with an acute SARS‐CoV‐2 infection that successfully managed by dose reduction of immunosuppressive medication.
Figure 1
Loading...